First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases

Archives of Surgery

Volumn 143, Issue 4, 2008, Pages 352-358

  Galizia, Gennaro ^a   Lieto, Eva ^a   Orditura, Michele ^a   Castellano, Paolo ^a   Imperatore, Vincenzo ^a   Pinto, Margherita ^a   Zamboli, Anna ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; INTESTINE TUMOR; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; CANCER STAGING; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; LIVER FUNCTION TEST; LIVER TUMOR; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 42449117636     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.143.4.352     Document Type: Article

References (30)

1. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23(28):7125-7134.
2. Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000;135(5):530-535.
3. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254-259.
4. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108-113.
5. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003;12(1):165-192.
6. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23(7):1358-1364.
7. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol. 2005;12(8):637-645.
8. Chafai N, Chan CLH, Bokey EL, Dent OF, Sinclair G, Chapuis PH. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? Colorectal Dis. 2005;7(2):176-181.
9. Petrelli NJ. Expressing the prochemotherapy position on treatment of synchronous colorectal metastases in the asymptomatic patient. Ann Surg Oncol. 2006;13(2):137-139.
10. Kemeny MM. Expressing the surgery first position on treatment of synchronous colorectal metastases in the asymptomatic patient. Ann Surg Oncol. 2006;13(2):140-141.
11. Nash GM, Saltz LB, Kemeny NE, et al. Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol. 2002;9(10):954-960.
12. Kuo LJ, Leu SY, Liu MC, Jian JJ, Hongiun Cheng S, Chen CM. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum. 2003;46(12):1646-1652.
13. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196(5):722-728.
14. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6(7):651-657.
15. Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52(4):568-573.
16. Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28(5):434-437.
17. Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92(9):1155-1160.
18. Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89(4):211-217.
19. Greene FL, Page DL, Fleming ID, et al; American Joint Committee on Cancer. Cancer Staging Manual. eds 6th ed. New York, NY: Springer; 2002:113-123.
20. Jass JR, Ajioka JP, Chan YF, et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology. 1996;28(6):543-548.
21. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655-1659.
22. Shaw MC, Wolfe CD, Devaja O, Raju KS. Development of an evidence-based algorithm for the management of ovarian cancer. Eur J Gynaecol Oncol. 2003;24(2):117-125.
23. Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O'Riordain DS. Nonoperative management of the primary tumor in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88(10):1352-1356.
24. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93(7):872-878.
25. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644-658.
26. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC), final results of a phase III study [abstract 494]. Proc Am Soc Clin Oncol. 2001;20:124.
27. Alberts SR, Horwath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a north central cancer treatment group phase II study. J Clin Oncol. 2005;23(36):9243-9249.
28. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888-4896.
29. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23(33):8490-8499.
30. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/ folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13(1):58-65.